Kyverna reports positive one-year CAR-T results for rare stiff person syndrome, supporting FDA filing
read at Endpoints ↗Positive readoutPositive
Kyverna Therapeutics announced that its CAR-T therapy for stiff person syndrome showed positive results after one year of treatment.
The trial involved patients with the rare autoimmune disorder, which affects roughly 6,000 people in the United States and is characterized by painful muscle spasms and stiffness.
The favorable data are intended to strengthen the company's upcoming submission to the U.S. Food and Drug Administration for potential approval.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T”
read at Endpoints ↗87 words · retrieved Sep 24
comments(0)
5-min edit window · permanent after that